By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Threshold Pharmaceuticals, Inc. 

170 Harbor Way
Suite 300
South San Francisco  California  94080-6108  U.S.A.
Phone: 650-474-8200 Fax: 650-474-2529


SEARCH JOBS


Industry
Pharmaceutical






Company News
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Cantor Fitzgerald Healthcare Conference 7/2/2015 10:42:18 AM
ASCO15: Threshold Pharmaceuticals, Inc. (THLD) Presents Encouraging Preliminary Phase 2 Data In Multiple Myeloma At ASCO 6/1/2015 2:41:01 PM
Threshold Pharmaceuticals, Inc. (THLD) Announces Presentation And Webcast At The Jefferies and Co. 2015 Healthcare Conference 5/27/2015 10:34:49 AM
Threshold Pharmaceuticals, Inc. (THLD) Announces Clinical Update On Evofosfamide In Relapsed/Refractory Multiple Myeloma To Be Presented At ASCO 2015 5/14/2015 1:08:07 PM
Threshold Pharmaceuticals, Inc. (THLD)' Partner Merck KGaA (MKGAF.PK), Darmstadt, Germany, Receives FDA Fast Track Designation For Evofosfamide For The Treatment Of Patients Living With Advanced Pancreatic Cancer 5/12/2015 9:56:48 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports First Quarter 2015 Financial And Operational Results 4/30/2015 8:34:32 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Preclinical Data Suggesting That TH-4000 May Overcome Resistance To Conventional EGFR Tyrosine Kinase Inhibitors 4/23/2015 11:45:48 AM
Threshold Pharmaceuticals, Inc. (THLD) To Host Analyst And Investor Day On April 24 In New York City 4/17/2015 10:51:00 AM
Threshold Pharmaceuticals, Inc. (THLD) To Present Data Supporting Planned Phase 2 Trials Of TH-4000, A Hypoxia-Activated, Irreversible EGFR Tyrosine Kinase Inhibitor 3/19/2015 11:33:56 AM
Threshold Pharmaceuticals, Inc. (THLD) Reports Fourth Quarter And Year End 2014 Financial And Operational Results 3/3/2015 9:57:58 AM
12345678910...
//-->